BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22701616)

  • 1. Acute progression of BCR-FGFR1 induced murine B-lympho/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage.
    Ren M; Tidwell JA; Sharma S; Cowell JK
    PLoS One; 2012; 7(6):e38265. PubMed ID: 22701616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
    Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
    Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.
    Murati A; Arnoulet C; Lafage-Pochitaloff M; Adélaide J; Derré M; Slama B; Delaval B; Popovici C; Vey N; Xerri L; Mozziconacci MJ; Boulat O; Sainty D; Birnbaum D; Chaffanet M
    Int J Oncol; 2005 Jun; 26(6):1485-92. PubMed ID: 15870860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase.
    Ren M; Li X; Cowell JK
    Blood; 2009 Aug; 114(8):1576-84. PubMed ID: 19506298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old mice retain bone marrow B1 progenitors, but lose B2 precursors, and exhibit altered immature B cell phenotype and light chain usage.
    Alter-Wolf S; Blomberg BB; Riley RL
    Mech Ageing Dev; 2009 Jun; 130(6):401-8. PubMed ID: 19428460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A subfraction of B220(+) cells in murine bone marrow and spleen does not belong to the B cell lineage but has dendritic cell characteristics.
    Nikolic T; Dingjan GM; Leenen PJ; Hendriks RW
    Eur J Immunol; 2002 Mar; 32(3):686-92. PubMed ID: 11857343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute leukemia showing t(8;22)(p11;q11), myelodysplasia, CD13/CD33/CD19 expression and immunoglobulin heavy chain gene rearrangement.
    Shimanuki M; Sonoki T; Hosoi H; Watanuki J; Murata S; Mushino T; Kuriyama K; Tamura S; Hatanaka K; Hanaoka N; Nakakuma H
    Acta Haematol; 2013; 129(4):238-42. PubMed ID: 23328683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
    Ren M; Qin H; Ren R; Tidwell J; Cowell JK
    Cancer Res; 2011 Dec; 71(23):7312-22. PubMed ID: 21937681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.
    Ren M; Qin H; Ren R; Cowell JK
    Leukemia; 2013 Jan; 27(1):32-40. PubMed ID: 22781593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotyping of Murine Precursor B-Cell Leukemia/Lymphoma: A Comparison of Immunohistochemistry and Flow Cytometry.
    Janke LJ; Mullighan CG; Dang J; Rehg JE
    Vet Pathol; 2019 Nov; 56(6):950-958. PubMed ID: 31170889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
    Hao SX; Ren R
    Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biphenotypic B-lymphoid/myeloid cells expressing low levels of Pax5: potential targets of BAL development.
    Simmons S; Knoll M; Drewell C; Wolf I; Mollenkopf HJ; Bouquet C; Melchers F
    Blood; 2012 Nov; 120(18):3688-98. PubMed ID: 22927250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice.
    Agerstam H; Järås M; Andersson A; Johnels P; Hansen N; Lassen C; Rissler M; Gisselsson D; Olofsson T; Richter J; Fan X; Ehinger M; Fioretos T
    Blood; 2010 Sep; 116(12):2103-11. PubMed ID: 20554971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.
    Kelly LM; Liu Q; Kutok JL; Williams IR; Boulton CL; Gilliland DG
    Blood; 2002 Jan; 99(1):310-8. PubMed ID: 11756186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.
    Ren M; Qin H; Kitamura E; Cowell JK
    Blood; 2013 Aug; 122(6):1007-16. PubMed ID: 23777766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature.
    Kumar KR; Chen W; Koduru PR; Luu HS
    Am J Clin Pathol; 2015 May; 143(5):738-48. PubMed ID: 25873510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice.
    Ren M; Qin H; Wu Q; Savage NM; George TI; Cowell JK
    Int J Cancer; 2016 Aug; 139(4):836-40. PubMed ID: 27005999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.